HU6

HU6 is an orally-administered, liver-targeted mitochondrial uncoupler being developed by Rivus Pharmaceuticals as the lead candidate in a class the company describes as 'controlled metabolic accelerators' (CMAs) or controlled mitochondrial uncouplers. The compound aims to recapture the metabolic-rate-elevating benefits of 2,4-dinitrophenol (DNP) — known to dramatically increase basal metabolic rate but with a fatal therapeutic window — while engineering out the systemic toxicity that has made DNP unviable as a therapeutic.

HU6 is in active Phase 2 development across three indications. The M-ACCEL trial in obesity reported Phase 2a data showing favorable metabolic and weight effects. The HuMAIN-HFpEF trial in heart failure with preserved ejection fraction reported Phase 2a data showing improvements in metabolic and functional endpoints. The HuMAIN-MASH trial is evaluating HU6 in metabolic dysfunction-associated steatohepatitis. Multiple readouts have come through 2024-2025 with more expected.

Mitochondrial uncouplers reduce the efficiency of ATP synthesis by allowing protons to leak across the inner mitochondrial membrane back into the matrix without passing through ATP synthase. The energy that would have been captured as ATP is instead dissipated as heat. The downstream effects: increased basal metabolic rate, increased fat oxidation, reduced hepatic triglyceride content, and improved metabolic flexibility.

The catastrophic problem with DNP is that it uncouples mitochondria throughout the body without selectivity — including in skeletal muscle and the central nervous system — and at supratherapeutic doses produces hyperthermia, cellular acidosis, and death. HU6 is engineered for tissue-selective accumulation (substantially liver-enriched) and for graded, controllable uncoupling effects within a therapeutic window. The 'controlled' in 'controlled mitochondrial uncoupler' is the entire pharmacologic story.

Phase 1 dose-escalation established the safety and pharmacokinetic profile that supported moving into Phase 2. Tolerability was favorable at the doses tested, without the hyperthermia signal that characterizes DNP exposure.

M-ACCEL Phase 2a in obesity reported weight loss and metabolic improvements with HU6 vs placebo. The magnitude is modest compared to GLP-1-class effects but achieved through an entirely different mechanism (output side rather than intake side of energy balance).

HuMAIN-HFpEF Phase 2a reported improvements in metabolic markers, NT-proBNP, and 6-minute walk distance — encouraging data for a condition with limited pharmacologic options. The HFpEF indication is particularly interesting because HFpEF biology is increasingly understood as a metabolic disease, and a mitochondrial-targeted agent fits that framing.

HuMAIN-MASH Phase 2 is evaluating hepatic fat reduction and liver-injury markers in MASH patients — overlapping mechanistically with what resmetirom achieves through TR-beta activation, but via a different pathway.

No Phase 3 readouts yet. The pivotal trials will determine whether the favorable Phase 2 signal holds up at scale.

HU6 is the most clinically advanced controlled mitochondrial uncoupler in development and represents the first serious attempt at a metabolically-active obesity therapy that works on the output side of energy balance. The Phase 2 data is encouraging across three indications; Phase 3 confirmation is the gating event. If approved, HU6 would substantially change the obesity-pharmacology landscape — particularly in combination with intake-side agents like the GLP-1 receptor agonists. The MASH and HFpEF programs may reach clinical reality earlier given less-crowded indication landscapes.